Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008

BMC Public Health

Julia Critchley⁵  Simon Capewell²  Martin O´Flaherty²  Kathleen Bennett⁶  Özgür Aslan¹  Yücel Demiral³  Sinem Doganay³  Hatice Şimşek³  Deniz Utku Altun³  Gül Gerçeklioğlu³  Hale Arık⁴  Kaan Sözmen³  Belgin Unal³ 

[1] Department of Cardiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey;Department of Public Health, University of Liverpool, Liverpool, UK;Department of Public Health, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey;Ordu Community Health Centre, Ordu, Turkey;Division of Population Health Sciences and Education, St George’s, University of London, London, UK;Department of Pharmacology & Therapeutics, Trinity College, Dublin, Ireland

关键词: Modelling;    Turkey;    Coronary heart disease management;    Coronary heart disease risk factors;    Coronary heart disease mortality;    Coronary heart disease;   

Others  :  1161498
DOI  :  10.1186/1471-2458-13-1135

 received in 2012-11-29, accepted in 2013-11-25,  发布年份 2013

【 摘 要 】

Background

Coronary heart disease (CHD) mortality rates have been decreasing in Turkey since the early 1990s. Our study aimed to determine how much of the CHD mortality decrease in Turkey between 1995 and 2008 could be attributed to temporal trends in major risk factors and how much to advances in medical and surgical treatments.

Methods

The validated IMPACT CHD mortality model was used to combine and analyse data on uptake and effectiveness of CHD treatments and risk factor trends in Turkey in adults aged 35–84 years between 1995 and 2008.

Data sources were identified, searched and appraised on population, mortality and major CHD risk factors for adults those aged 35–84 years. Official statistics, electronic databases, national registers, surveys and published trials were screened from 1995 onwards.

Results

Between 1995 and 2008, coronary heart disease mortality rates in Turkey decreased by 34% in men and 28% in women 35 years and over. This resulted in 35,720 fewer deaths in 2008.

Approximately 47% of this mortality decrease was attributed to treatments in individuals (including approximately 16% to secondary prevention, 3% angina treatments, 9% to heart failure treatments, 5% to initial treatments of acute myocardial infarction, and 5% to hypertension treatments) and approximately 42% was attributable to population risk factor reductions (notably blood pressure 29%; smoking 27%; and cholesterol 1%). Adverse trends were seen for obesity and diabetes (potentially increasing mortality by approximately 11% and 14% respectively). The model explained almost 90% of the mortality fall.

Conclusion

Reduction in major cardiovascular risk factors explained approximately 42% and improvements in medical and surgical treatments explained some 47% of the CHD mortality fall. These findings emphasize the complimentary value of primary prevention and evidence-based medical treatments in controlling coronary heart disease.

【 授权许可】

   
2013 Unal et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Turkish Statistical Institute (Turkstat) website: Statistics by theme/Population and demography/vital statistics/statistical tables and dynamic search/death statistics. http://tuikapp.tuik.gov.tr/adnksdagitapp/adnks.zul webcite
• [2]Koc I, Eryurt MA, Adalli T, Seckiner P: Türkiye’nin demografik dönüşümü Doğurganlık, Aile Planlaması, Anne-Çocuk Sağlığı ve Beş Yaş Altı Ölümlerdeki Değişimler: 1968–2008. Ankara: Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü; 2010. http://www.hips.hacettepe.edu.tr/TurkiyeninDemografikDonusumu_220410.pdf webcite
• [3]Ministry of Health: National Burden of Disease and Cost Effectiveness Study Burden of Disease Final Report, 2004 (in Turkish). Ankara: Refik Saydam Hygiene Center Presidency; 2004. http://ekutuphane.tusak.gov.tr/kitaplar/turkiye_hastalik_yuku_calismasi.pdf webcite
• [4]British Heart Foundation: Coronary Heart Disease Statistics 2010. Oxford; 2010. http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001546 webcite
• [5]Dinc G, Gerceklioglu G, Sozmen K, Arık H, Unal B: Decreasing trends in cardiovascular mortality in Turkey between 1995 and 2008. BMC Public Health 2013, 13:896. BioMed Central Full Text
• [6]Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR: Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ 2010, 88(2):120-130.
• [7]Unal B, Critchley J, Capewell S: Explaining the decline in coronary heart disease mortality in England and Wales, 1981–2000. Circulation 2004, 109:1101-1107.
• [8]Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S: Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005, 162(8):764-773.
• [9]Onat A, Senocak MS, Surdum-Avci G, Ornek E: Prevalence of coronary heart disease in Turkish adults. IntJCardiol 1993, 39(1):23-31.
• [10]Altun B, Arici M, Nergizoglu G, Derici U, Karatan O, Turgan C, Sindel S, Erbay B, Hasanoglu E, Caglar S: Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens 2005, 23(10):1817-1823.
• [11]Arici M, Turgan C, Altun B, Sindel S, Erbay B, Derici U, Karatan O, Erdem Y, Hasanoglu E, Caglar S: Hypertension incidence in Turkey (HinT): a population-based study. J Hypertens 2010, 28(2):240-244.
• [12]Satman I, Yilmaz T, Sengul A, Salman S, Salman F, Uygur S, Bastar I, Tutuncu Y, Sargin M, Dinccag N, et al.: Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002, 25(9):1551-1556.
• [13]Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J: Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013. doi:10.1007/s10654-013-9771-5
• [14]Ergor G, Soysal A, Sozmen K, Unal B, Uçku R, Kılıç B, et al.: Balcova Heart Study- Rationale and Methodology of the Turkish Cohort. Int J Public Health 2011, 57(3):535-542.
• [15]Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M: Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008, 34(1–3):36-51.
• [16]Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S: Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007, 61(4):548-553.
• [17]Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M: Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006, 6:92. BioMed Central Full Text
• [18]Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM, et al.: National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011, 377(9765):568-577.
• [19]Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, et al.: National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011, 377(9765):578-586.
• [20]The Ministry of Health of Turkey: Global Adult Tobacco Survey Turkey Report. Ankara; 2010. http://www.havanikoru.org.tr/dosya/Docs_Tutun_Dumaninin_Zararlari/GATS.pdf webcite
• [21]Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, et al.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378(9785):31-40.
• [22]Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, et al.: National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377(9765):557-567.
• [23]Capewell S, Beaglehole R, Seddon M, McMurray J: Explaining the decline in Coronary Heart Disease Mortality in Auckland, New Zealand between 1982 and 1993. Circulation 2000, 102:1511-1516.
• [24]Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S: Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007, 356(23):2388-2398.
• [25]Capewell S, O'Flaherty M: What explains declining coronary mortality? Lessons and warnings. Heart 2008, 94(9):1105-1108.
• [26]Tokgözoğlu LKE, Erol C, Ergene O: EUROASPIRE III Turkey Study Group: [EUROASPIRE III: a comparison between Turkey and Europe]. TurkKardiyolDernArs 2010, 38(3):164-172.
• [27]Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, Shengelia B: WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005, 83(11):820-829.
• [28]Capewell S, Morrison CE, McMurray JJ: Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999, 81(4):380-386.
• [29]Critchley J, Liu J, Zhao D, Wei W, Capewell S: Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004, 110:1236-1244.
• [30]Bennett K, Kabir Z, Unal B, Shelley E, Critchley J, Perry I, Feely J, Capewell S: Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985–2000. J Epidemiol Community Health 2006, 60(4):322-327.
• [31]Note by Turkish Statistical Institute: New method for 2010 population and housing census of Turkey considerations about data quality and coverage. http://www.unece.org/fileadmin/DAM/stats/documents/ece/ces/ge.41/2008/sp.3.e.pdf webcite
• [32]Razum O, Akgun S, Tezcan S: Cardiovascular mortality patterns in Turkey: what is the evidence? Soz Praventivmed 2000, 45(1):46-51.
• [33]Appendices for IMPACT CHD Mortality Model. http://www.liv.ac.uk/PublicHealth/sc/bua/impact.html webcite
• [34]Erem C, Yildiz R, Kavgaci H, Karahan C, Deger O, Can G, Telatar M: Prevalence of diabetes, obesity and hypertension in a Turkish population (Trabzon city). Diabetes Res Clin Pract 2001, 54(3):203-208.
• [35]Tezcan S, Altintas H, Sonmez R, Akinci A, Dogan B, Cakir B, Bilgin Y, Klor HU, Razum O: Cardiovascular risk factor levels in a lower middle-class community in Ankara, Turkey. Trop Med Int Health 2003, 8(7):660-667.
• [36]Republic of Turkey: Distribution of Inpatiens by 150 Selected Diseases in Turkey. Health Statistics Year Book. Kalkan Matbaacılık. Ankara; 2011. http://www.saglik.gov.tr/TR/dosya/1-72577/h/saglikistatistikleriyilligi2010.pdf webcite
• [37]Aslan BU, Karcioglu O, Aslan O, Ayrik C, Kulac E, Guneri S: [Does the short-term mortality differ between men and women with first acute myocardial infarction?]. AnadoluKardiyolDerg 2002, 2(4):284-290.
• [38]Badillioglu O, Unal B, Ucku R: Five-year incidence of coronary heart disease and risk factors in Güzelbahçe, İzmir. Turk J Public Health 2011, 9(3):129-132.
• [39]Aslan BU, Karcioglu O, Aslan O, Ayrik C, Kulac E, Guneri S: Does the short-term mortality differ between men and women with first acute myocardial infarction? Anadolu Kardiyol Derg 2002, 2(4):284-290.
• [40]Turkish Statistical Institute: Health Survey 2008 Report. Ankara: Turkish Statistical Institute Printing Division; 2010.
• [41]Turkish Statistical Institute: Health Survey 2010 Report. Ankara: Turkish Statistical Institute Printing Division; 2012.
• [42]Unal B, Sozmen K, Ucku R, Ergor G, Soysal A, Baydur H, Meseri R, Simsek H, Gerceklioglu G, Doganay S, et al.: High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anadolu Kardiyol Derg 2013, 13:9-17.
• [43]Ildızlı MKM, Yavuzgil O, Hasdemir C, Gürgün C, Kültürsay H: To what extent are we applying current medical treatment approaches in coronary artery disease? Arch Turk Soc Cardiol 2004, 32:542-549.
• [44]Mant J, Hicks N: Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ 1995, 311(7008):793-796.
• [45]Capewell S, Chalmers J, MacIntyre K: Social gradients in AMI mortality rates rates (per 100,000) in the Scottish population 1986–1995 (quintiles of deprivation in men). 2000. Personal communication
• [46]Capewell S, MacIntyre K, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ: Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986–95: a retrospective cohort study. Lancet 2001, 358(9289):1213-1217.
• [47]Capewell S, Livingston BM, MacIntyre K, et al.: Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000, 21(22):1833-1840.
• [48]Nichol MB, Venturini F, Sung JC: A critical evaluation of the methodology of the literature on medication compliance. Ann Pharmacother 1999, 33(5):531-540.
• [49]Briggs A: Economics notes: handling uncertainty in economic evaluation. BMJ 1999, 319(7202):120.
• [50]Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S: Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J 2009, 30(9):1046-1056.
• [51]Palmieri L, Bennett K, Giampaoli S, Capewell S: Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010, 100(4):684-692.
• [52]Liu JL, Maniadakis N, Gray A, Rayner M: The economic burden of coronary heart disease in the UK. Heart 2002, 88(6):597-603.
• [53]Capewell S, Unal B, Critchley JA, McMurray JJ: Over 20,000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients. Heart 2006, 92(4):521-523.
• [54]Erdem Y, Arici M, Altun B, Turgan C, Sindel S, Erbay B, Derici U, Karatan O, Hasanoglu E, Caglar S: The relationship between hypertension and salt intake in Turkish population: SALTURK study. Blood Press 2010, 19(5):313-318.
• [55]Ministry of Health of Turkey: National Tobacco Control Programme and Action Plan of Turkey 2008–2012. Ankara; 2008. http://www.tkd-online.org/PDFs/tobacco_plan_en.pdf webcite
• [56]Altun D, Sozmen K, Kalaca S, Unal B: How does obesity prevalence change in Turkey? -Oral presentation. Trabzon, Turkey: Congress Book; 2011:S046. [14th National Public Health]
• [57]Ministry of Health of Turkey: Obesity Prevention and Control Program of Turkey (2010–2014). Ankara: Kuban Matbaacilik Yayincilik; 2010. http://www.beslenme.gov.tr/content/files/home/obesity_prevention_and_control_program_of_turkey_2010_2014.pdf webcite
• [58]Ministry of Health of Turkey: Turkey diabetes prevention and control program 2011–2014. Ankara: Anıl Matbaası; 2011. http://www.saglik.gov.tr/HM/dosya/1-71375/h/turkiye-diyabet-onleme-ve-kontrol-programi.pdf webcite
• [59]Critchley JA, Capewell S: Why model coronary heart disease? Eur Heart J 2002, 23(2):110-116.
• [60]Unal B, Capewell S, Critchley JA: Coronary heart disease policy models: a systematic review. BMC Public Health 2006, 6:213. BioMed Central Full Text
• [61]Simsek H, Demiral Y, Aslan O, Unal B: Treatment uptake levels in the coronary heart disease patients at hospital discharge. Int J Cardiol 2011, 147:S156-S156.
• [62]Sonmez K, Akcay A, Akcakoyun M, Demir D, Elonu OH, Onat O, Duran NE, Gencbay M, Degertekin M, Turan F: Distribution of therapeutic procedures and choice of drug therapies in patients with angiographically confirmed coronary artery disease. AnadoluKardiyolDerg 2002, 2(1):18-23. AXVI
• [63]Fichtenberg CM, Glantz SA: Association of the California Tobacco Control Program with Declines in Cigarette Consumption and Mortality from Heart Disease. N Engl J Med 2001, 343(24):1772-1777.
• [64]Critchley J, Capewell S: Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004., 1CD003041
• [65]Law MR, Wald NJ, Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994, 308(6925):367-372.
• [66]Capewell S, O'Flaherty M: Mortality falls can rapidly follow population-wide risk factor changes. Lancet 2011, 378(9793):752-753.
• [67]The Ministry of Health of Turkey: Prevention and Control Program for Cardiovascular Diseases: Strategic Plan and Action Plan for the Risk Factors. Ankara; 2009. http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/t4.pdf webcite